Skip to main content
v2026.11,986 entries · CC-BY 4.0

TAME Trial: Targeting Aging with Metformin

Explore the TAME trial design, targeting aging with metformin through composite clinical endpoints, FDA multi-morbidity models, and geroscience protocols.

Written and maintained by CASRAI Editorial Board

Published

On this page

The TAME trial (Targeting Aging with Metformin) is a landmark multi-center clinical study designed to test whether the generic biguanide metformin can delay the onset of multiple age-related chronic diseases simultaneously in older adults without diabetes. Led by geroscience researchers at the Albert Einstein College of Medicine in coordination with the American Federation for Aging Research, the trial evaluates approximately 3,000 participants aged 65 to 79 across a composite primary endpoint of cardiovascular events, cancer, cognitive decline, and all-cause mortality over a multi-year treatment period.

This page describes clinical trial designs, pharmacologic research, and general drug evaluation frameworks; it is not individual medical advice.

Short answer

The TAME trial represents a fundamental paradigm shift in translational geroscience and clinical trial design. Rather than addressing chronic degenerative illnesses in isolation through traditional disease-specific protocols, TAME investigates whether targeting the fundamental biological processes of aging with extended-release metformin can extend human healthspan. By measuring the delay in time to first occurrence across a cluster of major chronic conditions, the study seeks to establish an FDA-accepted regulatory model for approving therapeutics that target multi-morbidity and underlying cellular senescence.

Definition and scope of the TAME trial

The Targeting Aging with Metformin trial is structured as a prospective, randomized, double-blind, placebo-controlled clinical trial conducted across approximately fourteen leading academic medical centers throughout the United States. Its primary objective is to prove that biological aging is modifiable in humans using a well-characterized, generic pharmacologic intervention. Unlike conventional phase 3 oncology or cardiology trials that recruit cohorts defined by a single acute or progressive diagnostic ICD code, TAME recruits non-diabetic individuals who are at risk for common chronic diseases simply by virtue of chronological age.

The clinical protocol focuses on participants aged 65 to 79 who have either established mild chronic morbidity or elevated risk profiles, excluding patients with preexisting type 2 diabetes so that metabolic glucose lowering does not obscure broader systemic geroprotective actions. By evaluating extended-release metformin administered daily alongside matching placebos, investigators track the progression of multi-morbidity over four to six years. The trial scope encompasses clinical endpoints, functional assessments such as gait velocity and grip dynamometry, and continuous biobanking through the companion TAME-Bio initiative to evaluate biological aging signatures.

How the trial works in clinical and regulatory practice

To understand the execution of the TAME trial, clinical research coordinators and laboratory investigators examine both its mechanistic biological rationale and its complex regulatory framework. Mechanistically, metformin acts on multiple conserved hallmarks of aging. At the cellular level, the drug modulates hepatic and systemic metabolism by stimulating AMP-activated protein kinase (AMPK), inhibiting complex I of the mitochondrial respiratory chain, downregulating the mammalian target of rapamycin (mTOR) signaling pathway, and suppressing nuclear factor kappa B (NF-κB)-mediated inflammation. These upstream interventions reduce reactive oxygen species production, diminish circulating inflammatory cytokines (including interleukin-6 and tumor necrosis factor alpha), attenuate cellular senescence, and support genomic integrity.

From a regulatory standpoint, the U.S. Food and Drug Administration does not recognize “aging” as a disease or valid therapeutic indication. Because aging lacks an ICD-10 code, pharmaceutical sponsors have historically lacked an approval pathway to claim that a candidate molecule extends lifespan or slows aging. In landmark regulatory discussions between trial leaders and the FDA Center for Drug Evaluation and Research, investigators formulated an innovative solution: using an event-driven composite endpoint that aggregates standard, recognized clinical outcomes. Under this design, the primary outcome is not “retardation of aging” in the abstract, but the statistically validated extension of time to the first occurrence of any major age-related disease.

This design validates the geroscience hypothesis in a human population. The geroscience hypothesis posits that because advanced age is the predominant shared risk factor for virtually all chronic non-communicable diseases, intervening in fundamental biological aging mechanisms will simultaneously postpone cardiovascular illness, neurodegeneration, metabolic failure, and neoplastic transformation, rather than merely substituting one fatal disease for another.

Composite endpoint components and diagnostic criteria

The TAME primary outcome relies on rigorous adjudication protocols across multiple clinical domains. Rather than monitoring a single surrogate laboratory marker, independent blinded adjudication committees evaluate medical records, diagnostic imaging, and pathology reports to verify event arrival. The table below outlines the core diagnostic components included within the primary composite endpoint architecture, their standard clinical adjudication requirements, and their biological relationship to aging mechanisms.

Disease Category Specific Clinical Event Components Adjudication Criteria and Diagnostic Standards Targeted Geroscience Mechanism
Cardiovascular Events Myocardial infarction, acute ischemic stroke, congestive heart failure hospitalization, peripheral artery revascularization Elevated cardiac biomarkers (troponin I/T), diagnostic ECG changes, neuroimaging (MRI/CT), clinical hemodynamic guidelines Endothelial dysfunction, vascular stiffening, chronic vascular inflammation, mitochondrial oxidative stress
Malignancies Invasive solid tumors and hematologic cancers (excluding non-melanoma skin carcinomas) Histopathologic tissue biopsy confirmation, standardized clinical oncology staging (TNM classification) Genomic instability, cellular senescence escape, altered nutrient sensing, immune surveillance decline
Cognitive Impairment Incident mild cognitive impairment (MCI), vascular dementia, Alzheimer-type dementia transitions Standardized neuropsychological test batteries, DSM/NIA-AA diagnostic criteria, functional impairment scales Neuroinflammation, microvascular cerebral disease, synaptic loss, proteostasis failure
Mortality All-cause mortality Official death certificates, primary autopsy reports, or verified clinical records Terminal cumulative physiologic frailty, multi-system biological reserve depletion

By compiling these distinct clinical events into a unified time-to-event statistical survival analysis (such as Cox proportional hazards modeling), the trial maintains sufficient statistical power without requiring an impractically large cohort or decades of observation. Each participant contributes to the primary composite upon experiencing their first verified event, after which secondary longitudinal outcomes continue to track functional status and overall survival.

Where it matters for research labs, clinical trials, and biospecimen protocols

The methodology developed for TAME directly impacts how academic research centers, central clinical laboratories, and clinical research organizations design modern geroscience investigations. A central operational pillar of the trial is the TAME-Bio protocol, which establishes standardized biobanking procedures for multi-site longitudinal research. Participating trial sites collect serial biospecimens—including fasting plasma, serum, peripheral blood mononuclear cells (PBMCs), and genomic DNA—under rigorous cold-chain standard operating procedures.

These biospecimens allow laboratories to quantify circulating biomarkers of aging and track molecular changes across treatment arms. Core analytical workflows include:

  • Systemic Inflammatory Profiling: Measuring high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumor necrosis factor receptor 1 (TNFR1) using high-precision multiplex electrochemiluminescence immunoassay platforms.
  • Epigenetic Clock Metrics: Extracting PBMC genomic DNA to evaluate DNA methylation patterns (such as Horvath, Hannum, PhenoAge, and GrimAge algorithms) to assess whether metformin modulates biological epigenetic age acceleration.
  • Metabolic and Proteomic Biomarkers: Assessing insulin-like growth factor 1 (IGF-1), insulin-like growth factor-binding protein 1 (IGFBP-1), fasting insulin, and high-throughput aptamer- or antibody-based proteomic panels.
  • Cellular Senescence Markers: Evaluating circulating senescence-associated secretory phenotype (SASP) components and cellular expression of cyclin-dependent kinase inhibitors (such as p16INK4a and p21CIP1).

For clinical trial operators and institutional review boards, TAME establishes standard operating frameworks for managing multi-morbidity studies. Protocols must account for polypharmacy interactions, renal monitoring protocols, and dynamic adjudication across hospital networks without compromising protocol adherence or subject retention.

Common misunderstandings about TAME and metformin longevity

Public interest in longevity pharmacology has generated significant confusion regarding what the TAME trial is designed to prove and how metformin behaves outside of diabetic populations. Clarifying these misunderstandings is essential for research staff and clinicians evaluating geroscience literature.

First, TAME is not designed to prove that metformin is a universal “reversing elixir” for human aging. Metformin does not stop biological aging or induce cellular rejuvenation; rather, it acts as a geroprotective agent that attenuates specific pathways of damage accumulation, potentially compressing morbidity toward the end of life. Preclinical rodent studies demonstrate modest lifespan extension when initiated in middle age, but the primary clinical payoff in humans is healthspan extension—postponing the onset of disabling diseases.

Second, retrospective observational data from diabetic populations cannot be assumed to apply directly to healthy non-diabetic humans. Historical observational studies frequently reported that diabetic patients on metformin exhibited lower all-cause mortality and reduced cancer rates compared to non-diabetic controls. However, subsequent methodological reviews demonstrated that many of these studies suffered from severe immortal time bias, confounding by indication, and survival selection effects. Controlled clinical trials like TAME are necessary precisely because observational epidemiology cannot eliminate residual confounding in longevity research.

Third, metformin is not devoid of physiological trade-offs. In healthy older adults undergoing endurance exercise training, randomized physiological studies have noted that metformin can blunt mitochondrial respiratory adaptations in skeletal muscle and modestly attenuate gains in cardiorespiratory fitness (peak oxygen uptake, VO2 max). Consequently, applying metformin indiscriminately to healthy, highly active individuals without metabolic impairment remains controversial and unsupported by prospective phase 3 clinical data.

What is the latest research on metformin?

Contemporary biomedical research on metformin extends far beyond its traditional identity as a glucose-lowering biguanide for diabetes. In geroscience, recent molecular investigations focus on its direct interactions with mitochondrial complex I, cellular energy sensors, and the microbiome. Clinical studies such as the Metformin in Longevity Study (MILES, NCT02432287) analyzed muscle and subcutaneous adipose tissue biopsies from older adults before and after metformin treatment, discovering that the drug induces transcriptomic shifts in pathways regulating metabolic signaling, DNA repair, mitochondrial respiration, and inflammatory cascades.

Furthermore, large-scale multi-omics analyses reveal that metformin alters gut microbiota composition—increasing the abundance of short-chain fatty acid-producing species like Akkermansia muciniphila—which contributes to systemic metabolic homeostasis and immune modulation. In oncology, prospective clinical studies continue to evaluate metformin as an adjuvant therapy in breast, prostate, and colorectal cancers, investigating whether AMPK activation can suppress tumor proliferation in hyperinsulinemic microenvironments.

Research into metformin and amyotrophic lateral sclerosis (ALS) has revealed a critical molecular link, particularly in cases driven by the C9orf72 genetic mutation. The hexanucleotide repeat expansion (GGGGCC) within the C9orf72 gene is the most common genetic cause of familial ALS and frontotemporal dementia (FTD). This mutation produces neurotoxic dipeptide repeat proteins through an unconventional, non-canonical translation process known as repeat-associated non-AUG (RAN) translation.

In groundbreaking preclinical research published in 2020 by Zu and colleagues in the Proceedings of the National Academy of Sciences, investigators demonstrated that metformin inhibits this toxic RAN translation by targeting double-stranded RNA-activated protein kinase (PKR) signaling pathways. By attenuating PKR phosphorylation, metformin significantly reduced the accumulation of neurotoxic dipeptide repeat proteins (such as poly-glycine-arginine and poly-glycine-alanine) and mitigated neurodegenerative pathology in C9orf72 mouse models. These preclinical discoveries spurred targeted phase 2 clinical investigations to explore the safety, tolerability, and biological efficacy of metformin in patients carrying the C9orf72 expansion, establishing an important translational avenue in neurodegenerative geroscience.

Is metformin still first line for diabetes in 2026?

In current clinical practice, metformin remains a foundational first-line pharmacologic agent for type 2 diabetes, but treatment guidelines from the American Diabetes Association (ADA) have shifted from a universal, rigid default to a comorbidity-driven algorithm. For adults diagnosed with type 2 diabetes who do not present with complex organ-system comorbidities, metformin combined with comprehensive lifestyle interventions remains the recommended first-line standard of care due to its proven efficacy in lowering glycated hemoglobin (A1C), weight neutrality, low hypoglycemia risk, decades of safety data, and cost-effectiveness.

However, for patients presenting with or at high risk for atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), clinical practice guidelines now recommend initiating organ-protective agents—specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists with demonstrated clinical trial benefits—either in combination with metformin or independently, regardless of the patient’s baseline A1C. Thus, while metformin retains its role as a premier baseline glucose-lowering therapy worldwide, it is increasingly paired or sequenced with disease-modifying agents to protect cardiorenal health.

How many years can you safely take metformin?

Metformin can be safely administered continuously for decades when accompanied by appropriate clinical laboratory monitoring. The longest longitudinal prospective randomized data in humans comes from the Diabetes Prevention Program (DPP) and its long-term extension, the Diabetes Prevention Program Outcomes Study (DPPOS), where participants with prediabetes were tracked over fifteen to twenty-plus years of continuous metformin administration (850 mg twice daily). The DPPOS established that extended, multi-decade metformin therapy maintains an excellent overall safety profile without cumulative hepatic, cardiovascular, or oncologic toxicity.

Long-term safe administration requires attention to two primary clinical considerations:

  1. Renal Function Monitoring: Metformin is eliminated unchanged by the kidneys via glomerular filtration and tubular secretion. If renal function declines significantly, drug accumulation can increase the risk of lactic acidosis. Current clinical guidelines mandate monitoring estimated glomerular filtration rate (eGFR) at least annually. Metformin is considered safe when eGFR remains above 45 mL/min/1.73 m²; dose reduction is recommended between 30 and 44 mL/min/1.73 m², and treatment is contraindicated when eGFR drops below 30 mL/min/1.73 m².
  2. Vitamin B12 Deficiency Screening: Long-term metformin use interferes with calcium-dependent ileal membrane absorption of the vitamin B12-intrinsic factor complex. Landmark findings from the DPPOS published in the Journal of Clinical Endocrinology and Metabolism revealed that the risk of biochemical vitamin B12 deficiency increases cumulatively by approximately 13% for each year of continuous metformin use. Routine periodic screening of serum vitamin B12 levels is recommended to prevent insidious megaloblastic anemia and peripheral neuropathy.

To examine how TAME compares to other major clinical longevity and geroscience investigations across design parameters and outcome architectures, consult the data table below.

Frequently asked questions

What does the TAME trial stand for?

TAME stands for Targeting Aging with Metformin, a nationwide geroscience clinical trial coordinated through the American Federation for Aging Research and academic medical centers.

Why was metformin selected for the TAME trial instead of newer longevity drugs?

Metformin was selected because of its more than sixty-year history of clinical use, well-documented human safety record, broad affordability as a generic medication, and robust preclinical evidence showing it modulates multiple conserved hallmarks of aging.

What is the primary endpoint of the TAME trial?

The primary endpoint is an event-driven composite outcome measuring the time to the first occurrence of any major age-related chronic disease, specifically cardiovascular events, invasive malignancies, cognitive impairment or dementia, and all-cause mortality.

Who is eligible to participate in the TAME trial?

The trial design targets older adults aged 65 to 79 who do not have preexisting type 2 diabetes, ensuring that the observed clinical effects reflect systemic geroprotective mechanisms rather than glucose lowering alone.

How does the TAME trial influence FDA drug approval pathways?

By demonstrating that a drug can delay a composite cluster of age-related multi-morbidities, TAME establishes a regulatory precedent allowing future geroscience therapeutics to achieve FDA approval even though aging itself is not categorized as a distinct disease code.

Is metformin currently FDA-approved for anti-aging or life extension?

No, metformin is currently approved by the FDA solely for the management of type 2 diabetes mellitus. Its use for longevity, anti-aging, or multi-morbidity prevention remains investigational in clinical research settings.

Sources

Data: Geroscience and Longevity Clinical Trials Comparison

Comparative protocol parameters, intervention designs, sample sizes, and endpoint structures across landmark human geroscience and metabolic longevity clinical trials, compiled from published trial protocols, ClinicalTrials.gov registries, and peer-reviewed outcomes literature.

Period covered: 2015-2026. Coverage: United States.

Geroscience and Longevity Clinical Trials Comparison
Trial AcronymIntervention MoleculeTarget PopulationSample Size (participants)Primary Endpoint TypeFollow-Up Duration (years)Regulatory Precedent
TAMEMetformin extended-release (1500 mg/day)Older adults aged 65-79 without diabetes3000Composite multi-morbidity event delay6Multi-morbidity indication framework
MILESMetformin (1700 mg/day)Older adults aged 65-90 with impaired glucose tolerance14Adipose and muscle tissue transcriptomic pathways0.5Biological aging mechanism exploration
DPPOSMetformin (1700 mg/day) vs. LifestylePrediabetic cohort followed longitudinally3234Diabetes incidence and microvascular complications20Diabetes prevention and long-term safety profile
CALERIE25% Caloric RestrictionHealthy non-obese adults aged 21-50218Resting metabolic rate and core body temperature2Physiological aging biomarkers in non-obese humans

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about TAME Trial: Targeting Aging with Metformin

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →